Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16490477 | 0.89 | PIK3CA (0.31) | PIK3CA | |
| SCHEMBL12498978 | 0.75 | PDE4B (0.33) | PIK3CA | |
| SCHEMBL3473167 | 0.66 | TSHR (0.33) | — | |
| SCHEMBL16488953 | 0.66 | — | — | |
| SCHEMBL16490264 | 0.65 | — | — | |
| SCHEMBL7557979 | 0.63 | TLR8 (0.37) | — | |
| SCHEMBL12411196 | 0.63 | GAA (0.37) | PIK3CA | |
| SCHEMBL12496155 | 0.63 | — | — | |
| SCHEMBL12410702 | 0.62 | PIK3CA (0.39) | PIK3CA | |
| SCHEMBL24770460 | 0.62 | POLB (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | PIK3CA 1896/4885 |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | PIK3CA 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.